Abstract
We appreciate the opportunity to reply to the Letter to the Editor by Dimosiari and colleagues [1], commenting on our work [2]. We concur with them that the cardiovascular disease (CVD) risk of Janus kinase (JAK) inhibitors in patients with ankylosing spondylitis (AS) deserves attention.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have